awmsg logo



aflibercept (Zaltrap®)


Reference No. 456

Publication date:
09/06/2015


Last review date:
18/06/2018

Appraisal information

aflibercept (Zaltrap®) 25 mg/ml concentrate for solution for infusion


Company: Sanofi
BNF category: Malignant disease and immunosupression
NMG meeting date: 19/11/2014
AWMSG meeting date: 11/02/2015
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0315
Ratification by Welsh Government: 08/06/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Aflibercept (Zaltrap®) is not recommended for use within NHS Wales in combination with irinotecan/5 fluorouracil/folinic acid (FOLFIRI) chemotherapy for the treatment of adults with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen. The case for cost-effectiveness has not been proven. Refer to the NICE Technology Appraisal Guidance (TA307) which will continue to apply within NHS Wales.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download